Abivax Shares Plunge 32% After Rare Malignancy Reports Eclipse 50% Remission
ABVX•Abivax shares fell 32% after rare malignancy cases in its late-stage ulcerative colitis trial overshadowed obefazimod’s 50.8% and 51.3% remission rates at 25 mg and 50 mg. The malignancy events, although deemed unrelated, raised safety concerns that rattled investor sentiment.
1. Efficacy Results
In the 44-week Phase III trial, obefazimod achieved clinical remission in 50.8% of patients at the 25 mg dose and 51.3% at the 50 mg dose, compared with just 10.4% in the placebo group, significantly exceeding expectations and current treatment benchmarks.
2. Safety Concerns
The trial data included a small number of rare malignancy cases among participants, none of which were deemed treatment-related, but their presence prompted caution among investors evaluating the drug’s safety profile.
3. Market Reaction
Following publication of the trial results, Abivax shares fell more than 32% during early European trading, as investor focus shifted toward potential labeling risks tied to the malignancy events.
4. Analyst Commentary
Analysts noted obefazimod’s differentiated efficacy and potential competitive edge in ulcerative colitis but highlighted the malignancy signal as a possible overhang that could delay approval or require additional monitoring.
